Breast Cancer Research and Treatment最新文献

{"title":"Development and validation of a highly accurate multigene gene expression biomarker to predict chemotherapy response in primary triple-negative breast cancer.","authors":"Soukaina Amniouel, Mohsin Saleet Jafri","doi":"10.1007/s10549-026-07950-4","DOIUrl":"10.1007/s10549-026-07950-4","url":null,"abstract":"<p><strong>Purpose: </strong>Triple-negative breast cancer (TNBC) is an aggressive subtype lacking estrogen and progesterone receptors and HER2 amplification. Representing 10-15% of breast cancer cases, TNBC disproportionately affects Black and pre-menopausal women and is associated with poorer outcomes. With chemotherapy as the primary systemic treatment option, achieving a pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) is a key prognostic factor. However, TNBC biological heterogeneity complicates treatment response prediction. This study aimed to identify transcriptomic biomarkers predictive of NAC response in TNBC patients and evaluate machine-learning models for response classification.</p><p><strong>Methods: </strong>We performed transcriptomic profiling on tumors from 234 TNBC patients, divided into training 138 pCR,72 residual disease (RD) and test 9 pCR, 15 RD cohorts. Feature selection was conducted using LASSO regression and Boruta algorithms to identify robust biomarkers. Random forest and support vector machine (SVM) models were trained on the selected and evaluated on the independent test set.</p><p><strong>Results: </strong>Feature selection identified 21 overlapping biomarkers, including EPHB3, ATP5MJ, USP1, RANBP9, SLC11A2, S100P, PPP1R1A, ZIC1, NDRG2, SMARCA2, H2BC7, STK24, HBB, VPS45, H1, VEGFA, NFIB, ITGA6, RPRD1A, PRKD3, and ENSA, several of which have been implicated in TNBC progression and treatment resistance. In the test set, predictive performance was strong, with area under the curve (AUC) values of 91% for random forest and 89% for SVM.</p><p><strong>Conclusion: </strong>Transcriptomic profiling combined with machine learning provides a promising approach for predicting NAC response in TNBC. The identified biomarkers may inform precision treatment strategies and improve clinical outcomes in this high-risk patient population.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"217 1","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13021716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147509140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Automated calculation of background parenchymal enhancement as a biomarker of treatment responses and recurrence-free survival in breast cancer.","authors":"Yihui Zhu, Roham Hadidchi, Hien Quang Nguyen, Surya Hariharan, Jeremy Weiss, Wei Hou, Chris Chung, Ha Manh Luu, Siddarth Ragupathi, Takouhie Maldjian, Tim Q Duong","doi":"10.1007/s10549-026-07941-5","DOIUrl":"10.1007/s10549-026-07941-5","url":null,"abstract":"<p><strong>Purpose: </strong>To determine whether automated quantification of background parenchymal enhancement (BPE) from dynamic contrast-enhanced MRI (DCE-MRI) can serve as an imaging biomarker for clinical outcomes including overall survival (OS), recurrence-free survival (RFS), and pathological complete response (pCR) in breast cancer.</p><p><strong>Methods: </strong>The multi-institutional data consisted of 922 biopsy-confirmed invasive breast cancer patients from the Duke-Breast-Cancer-MRI dataset and 152 patients with whole-breast pre- (T₀) and/or post (T₃) DCE-MRI from the I-SPY2 dataset for validation. Automated fibroglandular tissue (FGT) segmentation and BPE quantification were performed on DCE-MRI. The optimal intensity enhancement threshold by volume-based method was established against four radiologist-defined BPE categories. The area under the curve (AUC) was obtained for classification of BPE categories. Cox proportional hazards models were used to predict OS and RFS. Logistic regression was used to predict pCR.</p><p><strong>Results: </strong>Peak-contrast BPE showed strong correlation with radiologist-defined BPE, achieving the best performance at a 55% signal enhancement threshold (AUC 0.70-0.86). The calculated BPE decreased after neoadjuvant chemotherapy. A reduction in calculated BPE grade after neoadjuvant chemotherapy was predictive of pCR for the high baseline BPE group (adjusted odds ratio = 5.88 [1.03, 33.33]) and for the low baseline BPE group (adjusted odds ratio = 6.54 [1.26, 33.94]). Baseline BPE was independently associated with improved OS (adjusted hazard ratio 0.58 [0.34, 0.99]) but not associated with RFS.</p><p><strong>Conclusion: </strong>Automated quantification of BPE from DCE-MRI provides an objective and reproducible imaging biomarker associated with treatment response and overall survival in breast cancer. These results support its potential utility for individualized risk stratification and therapeutic decision-making.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"216 3","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13009020/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147503209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of a sensorimotor-based, movement quality-focused intervention on functional mobility in breast cancer survivors: a multicenter randomized controlled trial.","authors":"Eun Joo Yang, Heoung Su Kim, Ha Ra Jeon, Mi Ri Suh, So Young Ahn, Jin A Yoon, So Young Lee, Yu Hui Won, Ji Young Lee, Seung Hyun Chung","doi":"10.1007/s10549-026-07952-2","DOIUrl":"10.1007/s10549-026-07952-2","url":null,"abstract":"<p><strong>Purpose: </strong>Breast cancer survivors frequently experience reductions in physical capacity and sensorimotor impairments following treatment. However, improvements in strength and endurance do not always translate into improvements in functional mobility and balance-related outcomes. This study evaluated whether a sensorimotor-based rehabilitation program emphasizing movement control (Rehabilitation through Movement and Perception, ReMAP) could improve functional mobility and postural stability in breast cancer survivors.</p><p><strong>Methods: </strong>In this multicenter randomized wait-list controlled trial, 71 breast cancer survivors (mean age 50.7 ± 8.9 years) with mild functional impairment who had completed curative breast cancer treatment at least 3 months prior to enrollment were assigned to a ReMAP intervention group (n = 41) or a wait-list control group (n = 30). The 8-week intervention consisted of supervised, low- to moderate-intensity sensorimotor exercises targeting postural alignment, coordination, and balance. Functional mobility was assessed using the Timed Up and Go (TUG) test. Secondary outcomes included handgrip strength and 6-min walk distance as indicators of physical capacity, disability assessed using the World Health Organization Disability Assessment Schedule (WHODAS 12), and postural stability quantified by kinematic measures of center-of-mass sway.</p><p><strong>Results: </strong>Participants in the ReMAP group demonstrated a significantly greater improvement in functional mobility than controls, with a larger reduction in TUG time at 8 weeks (group × time interaction: β =  - 0.97 s, 95% CI 1.93 to - 0.01; p = 0.049). Postural stability improved significantly, as evidenced by reductions in mediolateral and anteroposterior center-of-mass sway. No significant between-group differences were observed in handgrip strength, 6-min walk distance, or self-reported disability. Exploratory analyses suggested that improvements in TUG performance were more closely associated with changes in movement quality than with changes in physical capacity.</p><p><strong>Conclusions: </strong>A sensorimotor-based rehabilitation program improved functional mobility and postural stability in breast cancer survivors with relatively preserved physical capacity. Targeting movement quality may address key mechanisms underlying balance-related vulnerability in survivorship care.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"216 3","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147509573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rb expression in metastatic ER-positive breast cancer: implications for precision oncology.","authors":"Doaa Morrar, Dara Ross, Pedram Razavi, Edi Brogi, Fresia Pareja, Hannah Y Wen, Christopher J Schwartz","doi":"10.1007/s10549-026-07945-1","DOIUrl":"10.1007/s10549-026-07945-1","url":null,"abstract":"<p><strong>Purpose: </strong>The retinoblastoma protein (Rb) is a critical cell-cycle regulator, and its loss of function can lead to resistance to CDK4/6 inhibitors (CDK4/6i), which are the standard first-line treatment for estrogen receptor (ER)-positive metastatic breast carcinoma (mBC). Thus, identifying Rb-deficient mBC is crucial for optimal personalized breast cancer management. This study aimed to determine the prevalence of Rb loss by immunohistochemistry (IHC) in a cohort of ER + mBC and to assess its correlation with RB1 genetic inactivation.</p><p><strong>Methods: </strong>We analyzed Rb IHC in 50 consecutive ER-positive mBC. Histopathologic and clinical features were analyzed. p16 IHC was performed in a subset of Rb-deficient cases. Targeted next-generation tumor-normal sequencing (NGS) data using MSK-IMPACT were retrospectively analyzed in 38 mBCs.</p><p><strong>Results: </strong>Rb loss was identified in 20% (10/50) of mBC, and was either partial (8%, 4/50) or complete (12%, 6/50). In all evaluable cases (100%, 9/9), Rb loss was associated with p16 positivity. Neuroendocrine (NE) features were observed in 40% (4/10) of mBCs with Rb loss. MSK-IMPACT data were available for six Rb-deficient cases and revealed pathogenic RB1 alterations in two (33%). None of the tumors with preserved Rb expression (80%, 40/50) showed RB1 genetic alterations or NE features. Notably, one mBC case demonstrated disease progression on CDK4/6 inhibitor therapy, accompanied by acquired Rb loss and acquisition of an NE phenotype.</p><p><strong>Conclusion: </strong>Rb loss in mBC can be reliably detected by Rb IHC, especially when interpreted alongside p16, offering a rapid and cost-effective means of assessing Rb status. This approach may identify Rb-deficient tumors that are missed by conventional methods, such as next-generation sequencing, and help guide personalized therapeutic strategies in patients with mBC.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"216 3","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147503146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Telehealth utilization during the COVID-19 pandemic: comparing breast cancer survivors to non-cancer patients and implications for current practice.","authors":"Lashez A Hawkins, Ruvarashe P Rumano, Sharnell S Smith, Chloe M Beverly-Hery, James L Fisher, Akia Clark, Victoria Champion, Bridget A Oppong, Electra D Paskett","doi":"10.1007/s10549-026-07940-6","DOIUrl":"10.1007/s10549-026-07940-6","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;During the 2019 coronavirus (COVID-19) pandemic, in-person medical visits changed due to social distancing guidelines. Breast cancer (BC) patients, needing ongoing treatment or surveillance, faced increased challenges in accessing care. Telehealth became essential for providing convenient and cost-effective care while minimizing COVID-19 transmission. BC survivors, however, often value in-person visits for clinical exams. This study aimed to compare telehealth participation between patients with a history of BC and women without cancer history.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Adults aged 18 and older, including cancer patients, survivors, caregivers, and healthy volunteers, primarily from Ohio, were recruited with attention and inclusion of underserved and minority populations to complete a survey about COVID-19-related beliefs, practices, and knowledge. Recruitment involved (1) re-contacting participants from previous OSU studies (2) outreach via community partners and listservs to invite additional participants and caregivers. Sociodemographic characteristics by BC status were calculated using Chi square tests. Univariable and multivariable logistic regressions modeled association between the outcome of interest, telehealth participation, and BC status accounting for race, ethnicity, age, education, marital status, rurality, and insurance status.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The final sample included 2265 participants, with 43.7% having a history of BC. Significant demographic differences were observed between participants with and without a history of breast cancer. Those with a previous BC diagnosis were younger on average (55.6 vs. 57.9 years, p &lt; .001), had higher levels of educational attainment (p &lt; .001), were less often married and more often divorced/widowed/separated (p = .037), and were more likely to have private insurance only and less likely to have both public and private coverage (p &lt; .001). Telehealth use was lower during COVID-19 among BC survivors (41.5%) vs. those without cancer (63.9%) (p &lt; 0.001). In a multivariable model, factors that were statistically significantly associated with increased utilization of telehealth were Black race (OR = 1.90, p-value 0.036), having some college education (OR = 1.50, p-value 0.034), being married (OR = 1.61, p-value 0.009), and being currently employed (OR = 1.25, p-value 0.050). BC diagnosis or survivor status was associated with decreased odds of telehealth use (OR: 0.72, p = 0.023). Among breast cancer patients with complete data (n = 645 of the 989 total), more than half used telehealth, with video visits being slightly more common than phone visits. Logistic regression analyses revealed increased telehealth use among patients with a history of BC was associated with age &gt; 70, while decreased participation in telehealth was associated with higher educational status and having undergone surgical treatment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;We found","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"216 3","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13013313/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147509114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of CNS relapse following pathological complete response to neoadjuvant chemotherapy in early breast cancer.","authors":"Luciana de Moura Leite, Guilherme Rossato de Almeida, Monique Celeste Tavares, Marcelle Goldner Cesca, Fernando Augusto Batista Campos, Fernanda Alves de Oliveira, Debora Maciel Santana Dornellas, Erick F Saldanha, Paula Tavares Guimarães, Daniella Dias Sá de Arruda, Maria Fernanda Simões Devides de Held, Rafael Lima Viana, Francisca Giselle Rocha Moura, Simone Klug Loose, Sinara Figueiredo Silva, Rafaela Pirolli, Camilla Albina Zanco Fogassa, Bruna Raphaeli Silva Mattos, Solange Moraes Sanches, Vladmir C Cordeiro de Lima","doi":"10.1007/s10549-026-07915-7","DOIUrl":"10.1007/s10549-026-07915-7","url":null,"abstract":"<p><strong>Purpose: </strong>Pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) improves outcomes in breast cancer (BC); however it may not prevent brain metastases. We evaluated central nervous system (CNS) recurrence patterns in early-stage BC following NAC according to pCR.</p><p><strong>Methods: </strong>All consecutive stage I-III BC treated with NAC and surgery at a single center between 2007 and 2018 were analyzed. Endpoints included the impact of pCR on CNS recurrence across BC subtypes-hormone receptor-positive(HR)/HER2-negative, HER2-positive and triple-negative (TNBC), CNS recurrence patterns and overall survival (OS) after CNS relapse. Statistical comparisons included Fisher's Exact test, Chi-square, Kaplan-Meier, and regression analyses.</p><p><strong>Results: </strong>Among 1147 patients, 537 had HR-positive/HER2-negative, 301 HER2-positive, 309 TNBC, mostly stage III, treated with anthracycline + taxane NAC, and trastuzumab if HER2-positive. Three hundred sixty-five achieved pCR (59/537 HR-positive/HER2-negative, 158/301 HER2-positive, 148/309 TNBC). CNS recurrence occurred in 72 (6.2%) patients, with no difference between pCR and non-pCR (4.7 vs. 7.0%, p = 0.15). Across subtypes, there was no difference for HR-positive/HER2-negative (3.4 vs. 4%, p = 1.0), TNBC (5.4 vs. 9.3%, p = 0.2), however there was a reduction in HER2-positive (4.4 vs. 14.7%, p = 0.003) after pCR. Isolated CNS relapse was the predominant pattern of CNS metastasis (82.4%) in pCR, particularly in HER2-positive. Median OS after CNS relapse was 12 months. Multivariate analysis identified HER2-positive, TNBC, and cN2-3 status as independent predictors of CNS recurrence.</p><p><strong>Conclusion: </strong>Although pCR was not associated with a lower overall risk of CNS recurrence, it predicted a reduced risk in HER2-positive disease. Isolated CNS relapse predominated, suggesting a sanctuary effect.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"216 3","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13006468/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147497741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"House value as an individual socioeconomic indicator for breast cancer survival and late-stage diagnosis: a population-based cohort study from Northern Ireland.","authors":"Sarah M Baxter, Charlene M McShane, Stuart A McIntosh, Damien Bennett, Meenakshi Sharma, Lynne Lohfeld, Daniel R S Middleton, Gerard Savage, Deirdre Fitzpatrick, Ann McBrien, David McCallion, Anna Gavin, Chris R Cardwell","doi":"10.1007/s10549-026-07947-z","DOIUrl":"10.1007/s10549-026-07947-z","url":null,"abstract":"<p><strong>Purpose: </strong>Socioeconomic inequalities in breast cancer survival persist in the UK. Area-based deprivation measures may underestimate socioeconomic effects by assigning average deprivation levels to all area inhabitants. This study investigated associations between house value (individual-level) and area-based deprivation with breast cancer outcomes in Northern Ireland.</p><p><strong>Methods: </strong>Women diagnosed with breast cancer from 2011 to 2021 were identified using the Northern Ireland Cancer Registry. House value was determined from Valuation and Lands Agency property valuation data, and area-based deprivation from the Northern Ireland Multiple Deprivation Measure. The primary outcome was breast cancer-specific mortality. Secondary outcomes were stage at diagnosis and all-cause mortality. Cox regression models calculated adjusted hazard ratios (HR) and 95% confidence intervals (95% CIs) for mortality by house value category and deprivation, adjusting for confounders.</p><p><strong>Results: </strong>Among 12,766 women with breast cancer, women in the lowest versus highest house value category had a 60% increase in mortality (adjusted HR = 1.60 95% CI 1.34, 1.92; per 20 percentile decrease adjusted HR = 1.12 95% CI 1.08, 1.16) and were more likely diagnosed with stage 4 disease (7.5% versus 4.1%; P < 0.001). Women living in the most versus least deprived areas had a 26% increase in mortality (adjusted HR = 1.26 95% CI 1.08, 1.47; per 20 percentile decrease adjusted HR = 1.05 95% CI 1.01, 1.08) but had no difference in stage 4 disease (5.9% vs. 5.0%; P = 0.157).</p><p><strong>Conclusion: </strong>Individual-level house value demonstrated stronger associations with breast cancer outcomes than area-level deprivation, suggesting it may serve as a more sensitive indicator for monitoring health inequalities in cancer.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"216 3","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13005866/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147493633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study.","authors":"Norikazu Masuda, Hiroyuki Yasojima, Hiroko Bando, Takashi Yamanaka, Hideo Shigematsu, Masato Takahashi, Shigenori E Nagai, Mitsuya Ito, Tomoyuki Aruga, Mariko Tokiwa, Shigeru Imoto, Rikiya Nakamura, Hiroshi Ishiguro, Hidetaka Kawabata, Shigehira Saji, Hironori Haga, Satoshi Morita, Masakazu Toi","doi":"10.1007/s10549-026-07917-5","DOIUrl":"10.1007/s10549-026-07917-5","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate long-term outcomes for triple‑negative breast cancer (TNBC) patients enrolled in JBCRG-22.</p><p><strong>Methods: </strong>TNBC (cT1c-T3, cN0-1, M0) patients were stratified by homologous recombination deficiency (HRD) and germline BRCA mutation (gBRCAm) status. Group A patients (aged < 65 years with HRD-positive tumors, or those with gBRCAm, if available) were randomized to receive 4 cycles of weekly paclitaxel (group A1) or eribulin (group A2), both with carboplatin, followed by 4 cycles of anthracycline. Group B patients (aged < 65 years with HRD-negative tumors or aged ≥ 65 years) were randomized to receive 6 cycles of eribulin plus cyclophosphamide (group B1) or eribulin plus capecitabine (group B2). Five-year invasive disease-free survival (IDFS), distant disease-free survival (DDFS), and overall survival (OS) were assessed. Additionally, data were analyzed by biomarker levels including lymphocyte count (LC) and neutrophil-to-lymphocyte ratio (NLR).</p><p><strong>Results: </strong>Ninety-nine patients were followed for a median of 5.6 years. In patients who received eribulin-based therapy (groups A2 + B1 + B2), 5-year IDFS and OS rates, respectively, were 95% and 100% in patients who achieved pCR after neoadjuvant therapy (n = 20) and 71.4% and 80.2% in those who did not (n = 56), showing significantly better prognosis in the pCR cohort (p < 0.05). OS tended to be better in patients with baseline LC ≥ 1500/mm³ and NLR < 3, particularly in eribulin-treated patients, although differences were non-significant.</p><p><strong>Conclusions: </strong>These findings will help guide the development of eribulin-based neoadjuvant chemotherapy for selected TNBC patients. Our exploratory analysis of LC and NLR results may help inform clinical prediction models for eribulin-treated patients.</p><p><strong>Trial registration: </strong>The study has been registered with the University Hospital Medical Information Network Clinical Trials Registry ( https://www.umin.ac.jp/ctr/index-j.htm ) with unique trial number UMIN000023162. The Japan Breast Cancer Research Group trial number is JBCRG-22.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"216 3","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13002658/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147484494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: A Canadian real‑world, multi‑center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2‑negative advanced breast cancer.","authors":"Catherine Doyle, Ana Elisa Lohmann, Nayyer Iqbal, Jan-Willem Henning, Swati Kulkarni, Nadia Califaretti, John Hilton, Cristiano Ferrario, Nathaniel Bouganim, Mihaela Mates, Stephanie Guillemette, Ricardo Leite, Marc-Andre Caron, Francois Thireau, Andres Machado, Stephen Chia","doi":"10.1007/s10549-026-07934-4","DOIUrl":"10.1007/s10549-026-07934-4","url":null,"abstract":"","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"216 3","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13002762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147484443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Omission of axillary surgery in early breast cancer with negative lymph nodes: a systematic review and meta-analysis of randomized clinical trials.","authors":"Bárbara Bizzo Castelo, Luiz Gustavo Oliveira Brito, Renato Zocchio Torresan, Cássio Cardoso Filho, Giuliano Mendes Duarte","doi":"10.1007/s10549-026-07910-y","DOIUrl":"10.1007/s10549-026-07910-y","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate whether the omission of axillary surgery impacts clinical outcomes in patients with early-stage breast cancer and clinically negative lymph nodes.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis of randomized clinical trials (RCTs) comparing no axillary surgery with standard axillary interventions (sentinel lymph node biopsy [SLNB] or axillary dissection [AD]). This study followed PRISMA guidelines and was registered in PROSPERO (CRD420250653779). Searches were conducted in PubMed, Web of Science, and Embase through June 2025. Outcomes assessed included overall survival (OS), disease-free survival (DFS), and axillary recurrence (AR). Meta-analyses were performed using RevMan 5.4. Risk of bias was assessed using the RoB 2 tool.</p><p><strong>Results: </strong>Out of 853 records, seven RCTs including 8806 patients met the inclusion criteria. Among them, 2,915 patients underwent no axillary surgery, while 5891 received surgical axillary treatment. Two trials compared no surgery with SLNB, and five compared no surgery with AD. No significant differences were found in OS (OR = 1.02; 95% CI, 0.86-1.20; p = 0.84; I² = 36%) or DFS (OR = 0.80; 95% CI, 0.63-1.00; p = 0.05; I² = 63%). AR was significantly lower in the axillary surgery group (OR = 0.18; 95% CI, 0.10-0.31; p < 0.01; I² = 39%).</p><p><strong>Conclusion: </strong>The omission of axillary surgery in early-stage breast cancer with clinically negative lymph nodes does not negatively impact overall or disease-free survival. However, it is associated with a higher-though still low-risk of axillary recurrence.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":"216 3","pages":""},"PeriodicalIF":3.0,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12999590/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147479842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}